

1 **WO**

2

3

4

5

6

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF ARIZONA**

7

8

9

Jeffrey Timothy Landrigan,

No. CV-10-02246-PHX-ROS

10

Plaintiff,

**DEATH PENALTY CASE**

11

vs.

12

13

Janice K. Brewer, Governor of the State  
of Arizona; Charles L. Ryan, Director  
of the Arizona Department of Corrections;  
Ernest Trujillo, Warden, Arizona  
Department of Corrections - Eyman;  
Carson McWilliams, Warden, Arizona  
Department of Corrections - Florence;  
Does 1-50,

**ORDER GRANTING MOTION FOR A  
TEMPORARY RESTRAINING ORDER**

14

15

16

17

Defendants.

18

19

Plaintiff Jeffrey Timothy Landrigan, an Arizona inmate under sentence of death, is scheduled to be executed at 10:00 a.m. on Tuesday, October 26, 2010. On Thursday, October 21, 2010, he filed in this Court a civil rights complaint under 42 U.S.C. § 1983 alleging that the manner and means by which the Arizona Department of Corrections (“ADOC”) intends to execute him will violate his Eighth Amendment right to be free from cruel and unusual punishment and his Fourteenth Amendment right to due process. (Doc. 1.) He also moved for a temporary restraining order or preliminary injunction. (Doc. 3.)

20

21

22

23

24

25

The Court ordered expedited briefing, set oral argument for October 25, 2010, and invited Defendants to “voluntarily provide detailed information concerning the sodium thiopental it intends to use in Plaintiff’s execution” or explain their refusal to provide the

1 information. (Doc. 6 at 4-5.) Defendants chose not to provide the requested information.  
2 (Doc. 7.) The Court then issued an order vacating oral argument and directing Defendants  
3 to “immediately and publically disclose information concerning the sodium thiopental ADOC  
4 intends to use in Plaintiff’s execution.” (Doc. 11 at 2.) In particular, Defendants were to  
5 provide “the source of the drug, the drug’s expiration date, the *efficacy of the drug* for its  
6 intended purpose . . . and all available documentation concerning the manufacturer and its  
7 process for producing sodium thiopental.” (Doc. 11 at 4) (emphasis added).

8 On October 24, 2010, Defendants provided some of the requested information for *in*  
9 *camera* review. The Court issued an order directing Defendants to establish why the  
10 provided information should remain under seal. Defendants’ arguments in support of  
11 keeping this information under seal consist of repeated references to the Arizona law  
12 prohibiting the disclosure of the “identity of executioners and other persons.” A.R.S. § 13-  
13 757. (Doc. 17 at 3). Defendants did not assert that the information was privileged under  
14 federal law. Defendants have never provided any information regarding the efficacy of the  
15 sodium thiopental at issue.

16 On October 25, 2010, Defendant publicly provided the expiration date of the sodium  
17 thiopental and moved for reconsideration of the Order requiring the release of additional  
18 information. (Doc. 12). The motion refused to publicly disclose the additional information  
19 the Court ordered on the basis that by ordering the disclosure the Court had “improperly  
20 engraft[ed] a requirement that the State use FDA-approved drugs.” (Doc. 12 at 2). It is  
21 unclear how Defendants read the directive regarding disclosure as a statement by this Court  
22 that only FDA-approved drugs could be used.

23 Plaintiff opposed the motion for reconsideration, claiming the motion merely  
24 presented the same arguments Defendants had already presented. (Doc. 14 at 1-2).  
25 Defendants filed a reply, again the misconstruing the FDA issue.

## 26 BACKGROUND

27 In 1989, Plaintiff escaped from an Oklahoma prison, where he was serving time for  
28 second-degree murder, and shortly thereafter murdered Chester Dean Dyer in Arizona. He

1 was convicted by a jury of theft, second-degree burglary, and felony murder for causing the  
2 victim's death in the course of a burglary, and the trial judge sentenced him to death. The  
3 facts surrounding the crime are set forth in the Arizona Supreme Court's decision affirming  
4 the convictions and sentence on appeal. *See State v. Landrigan*, 176 Ariz. 1, 3-4, 859 P.2d  
5 111, 113-14 (1993).

6 Because Plaintiff committed his crime before November 23, 1992, under Arizona law  
7 he had the choice to be executed by either lethal injection or lethal gas. *See* A.R.S. § 13-  
8 757(B). According to his complaint, Plaintiff declined to choose. Consequently, ADOC  
9 must use lethal injection to execute Plaintiff. *Id.* Similar to other states, Arizona's protocol  
10 for execution by lethal injection requires sequential administration of sodium thiopental,  
11 pancuronium bromide, and potassium chloride. In 2007, seven Arizona death row prisoners  
12 challenged this protocol in a civil rights action filed under 42 U.S.C. § 1983. In 2009, United  
13 States District Court Judge Neil V. Wake granted summary judgment in favor of the State,  
14 concluding that Arizona's three-drug protocol is "substantially similar" to that approved by  
15 the Supreme Court in *Baze v. Rees*, 553 U.S. 35 (2008).<sup>1</sup> *See Dickens v. Brewer*, No. CV-07-  
16 1770-PHX-NVW, 2009 WL 1904294 (D. Ariz. Jul. 1, 2009) (unpublished order). During  
17 the *Dickens* litigation, the following facts concerning Arizona's three-drug protocol were  
18 undisputed:<sup>2</sup>

19 Sodium thiopental is an ultrafast-acting barbiturate that induces  
20 unconsciousness. An intravenous dose of one gram of sodium thiopental is  
21 considered to be lethal, and the five gram dose administered under the Arizona  
22 Protocol is eleven to eighteen times more than that required to produce a loss  
23 of consciousness. A *properly administered dose* of five grams of sodium  
24 thiopental will produce a deep and long-lasting anesthesia in all people and  
eventually will cause death from respiratory arrest and cardiac depression.  
When successfully delivered into the circulation in sufficient quantities,  
sodium thiopental causes depression of the nervous system that would permit

---

25 <sup>1</sup> Landrigan is not one of the plaintiffs in *Dickens v. Brewer*, which is presently  
26 on appeal in the Ninth Circuit Court of Appeals.

27 <sup>2</sup> Contrary to the instant proceedings, Defendants willingly engaged in  
28 significant discovery in the *Dickens* litigation, including detailed information about Arizona's  
protocol and the individuals involved in the execution process.

1 excruciatingly painful procedures to be performed without causing discomfort  
2 or distress. Assuming the IV line is placed correctly in the vein and the  
3 sodium thiopental is delivered successfully into the bloodstream, five grams  
4 of intravenous sodium thiopental alone would cause certain unconsciousness  
5 and ultimately death within a relatively short period and with little to no risk  
6 of significant pain.

7 Pancuronium bromide is a paralytic neuromuscular blocking agent that  
8 prevents any voluntary muscle contraction. Pancuronium bromide mitigates  
9 involuntary muscle spasms often caused by potassium chloride, which may be  
10 unpleasant for witnesses to watch. The dose administered for lethal injection  
11 in Arizona is thirteen to twenty-six times more than the therapeutic dose and  
12 is likely to cause respiratory failure and circulatory collapse. Pancuronium  
13 bromide does not affect consciousness, sensation, cognition, or the ability to  
14 feel pain and suffocation. Therefore, an individual who is not completely  
15 anesthetized when he receives a dose of pancuronium bromide at therapeutic  
16 level or greater would experience a feeling of shortness of breath or “air  
17 hunger” and would be unable to move or otherwise respond. If administered  
18 to a conscious person, pancuronium bromide would cause severe agony  
19 because the person would be unable to breathe for several minutes before  
20 losing consciousness. Further, where sodium thiopental is not properly  
21 administered in a dose sufficient to cause loss of consciousness for the  
22 duration of the execution procedure, the use of pancuronium bromide will do  
23 nothing to alleviate the extreme pain of the intravenous injection of  
24 concentrated potassium chloride.

25 Potassium chloride is a salt found in all tissues in the body and is  
26 critical for maintaining normal cellular function and the excitability of muscles  
27 and nerves. The dose administered for lethal injection in Arizona is six times  
28 more than the therapeutic dose and is very likely to cause skeletal muscle  
paralysis and cardiac arrest. If potassium chloride were administered to a  
conscious person, the person likely would experience a severe burning  
sensation in the vein in which it is injected. Furthermore, the person likely  
would experience chest pain after the potassium chloride reached the heart, but  
before the person lost consciousness as a result of lack of blood flow to the  
brain. Because potassium chloride stops the heart, it produces electrical  
inactivity (*i.e.*, a flatline) on the electrocardiogram (“EKG”), which may be  
observed remotely without needing to physically examine the inmate. Death  
from potassium chloride may be pronounced more quickly than if the inmate  
were given sodium thiopental alone and thus died from decreased oxygen  
delivery to critical organs such as the heart and brain.

22 *Id.* at \*11-12.<sup>3</sup> The Arizona protocol does not require the chemicals come from an FDA-  
23 approved source and apparently the issue was not raised in the *Dickens* litigation.

---

25 <sup>3</sup> Arizona’s three-drug protocol contains nine pages setting forth the “Preparation  
26 and Administration of Chemicals.” Therefore, the protocol recognizes the need for the  
27 proper care and handling of these chemicals. *Id.* at 9 (stating the chemicals must “be stored  
28 in a secured locked area that is temperature regulated and monitored to ensure compliance  
with manufacturer specifications”).

1 Nevertheless, Arizona's three-drug protocol specifies which drugs must be used. That is, the  
2 unstated assumption of the protocol's lengthy discussion of the chemicals is that the sodium  
3 thiopental used in executions will, in fact, be sodium thiopental and it will operate in its  
4 intended manner.

5 As the Supreme Court noted in *Baze*: "It is uncontested that, failing a proper dose of  
6 sodium thiopental that would render [a] prisoner unconscious, there is a substantial,  
7 constitutionally unacceptable risk of suffocation from the administration of pancuronium  
8 bromide and pain from the injection of potassium chloride." 553 U.S. at 53.

9 Around the same time the plaintiffs in *Dickens* filed suit in federal court, Plaintiff  
10 sought post-conviction relief in state court challenging Arizona's lethal injection protocol on  
11 state law grounds. Two years later, on October 8, 2009, the state superior court denied post-  
12 conviction relief, adopting in large part Judge Wake's ruling in *Dickens* and concluding that  
13 Arizona's three-drug protocol is "substantially similar" to that approved by the Supreme  
14 Court in *Baze*. Plaintiff sought discretionary review in the Arizona Supreme Court, which  
15 denied the petition on April 6, 2010.

16 Thereafter, the State moved the Arizona Supreme Court to issue a warrant of  
17 execution. Plaintiff opposed the motion in May 2010 on numerous grounds, including the  
18 pendency of federal appellate proceedings in *Dickens*. On September 15, 2010, Plaintiff  
19 supplemented his opposition with a motion to defer ruling on the State's request for a warrant  
20 of execution. He asserted for the first time that there was a nationwide shortage of sodium  
21 thiopental and that the court should delay ruling on the warrant request until the State had  
22 demonstrated that it possessed or could legally obtain the drugs necessary to carry out his  
23 execution in a manner consistent with Arizona's protocol.

24 On September 21, 2010, the Arizona Supreme Court issued a warrant of execution,  
25 setting Plaintiff's execution for October 26. In a separate order, the court denied Plaintiff's  
26 motion to defer ruling and directed the State to report by October 1 whether it possessed a  
27 sufficient quantity of all the drugs necessary to carry out the execution. On September 24,  
28 2010, Plaintiff's counsel wrote ADOC Director Charles Ryan requesting notice of the

1 manner and means by which it acquired, or intended to acquire, the necessary drugs.  
2 Director Ryan responded by letter stating only that ADOC would advise counsel and the  
3 Arizona Supreme Court no later than October 1 whether it had obtained the necessary  
4 chemicals.

5 On September 30, 2010, the State filed in the Arizona Supreme Court a letter from  
6 Director Ryan indicating that ADOC had obtained the necessary supply of drugs. Plaintiff  
7 then moved the Arizona Supreme Court to direct the State to provide: (1) a declaration  
8 indicating the amount and source of the sodium thiopental to be used in his execution; (2) a  
9 copy of the package label; (3) a copy of the lot number and expiration date; (4) all storage  
10 information, including location and temperature; (5) all chain-of-custody information from  
11 when the drug was acquired; and (6) assurances that none of the packages of drugs or  
12 chemicals will have been opened prior to Plaintiff's scheduled execution. He further  
13 requested that the State be ordered to adhere to its current written protocol, including the use  
14 of sodium thiopental, and to refrain from amending the protocol while his warrant of  
15 execution was pending. In response to this motion, the State submitted a declaration from  
16 Director Ryan stating that ADOC "lawfully obtained the necessary chemicals under its  
17 current written protocol – sodium thiopental, pancuronium bromide, and potassium chloride  
18 – in sufficient quantity for an execution." (Doc. 3, Ex. E.) The declaration further avowed  
19 that ADOC "intends to follow the current protocol as written." (*Id.*)

20 On October 20, 2010, the Arizona Supreme Court held oral argument on Plaintiff's  
21 motion for disclosure. During argument, counsel for the State declined to reveal where  
22 ADOC obtained the sodium thiopental for Plaintiff's execution but acknowledged that it was  
23 not obtained from or manufactured by Hospira, Inc., which Plaintiff alleges is the only  
24 manufacturer of sodium thiopental approved by the Food and Drug Administration ("FDA").  
25 The State further reiterated that the drug was "lawfully" obtained and was not expired.<sup>4</sup>  
26

---

27 <sup>4</sup> The precise method in which Defendants obtained the sodium thiopental at  
28 issue has not been disclosed. Sodium thiopental is a Schedule III controlled substance and,

1 Following argument, the Arizona Supreme Court summarily denied Plaintiff's disclosure  
2 motion without explanation. The next day Plaintiff initiated the instant proceedings.

### 3 DISCUSSION

4 In his § 1983 complaint, Plaintiff alleges that ADOC's use of sodium thiopental that  
5 was manufactured by a foreign source not approved by the FDA creates a substantial and  
6 unnecessary risk of serious harm in violation of his rights under the Eighth Amendment.  
7 Plaintiff further claims that ADOC's failure to provide him notice regarding the sodium  
8 thiopental it intends to use in his execution violates his right to due process under the  
9 Fourteenth Amendment. Finally, Plaintiff alleges that the administration by a medical doctor  
10 or other trained medical professional of non-FDA approved sodium thiopental from a foreign  
11 source demonstrates deliberate indifference to his right to be free from cruel and unusual  
12 punishment. Plaintiff has moved for a temporary restraining order or a preliminary  
13 injunction to enjoin his execution and to allow for litigation of these claims.

#### 14 I. Legal Standard

15 The standard for issuing a temporary restraining order is essentially the same as that  
16 for issuing a preliminary injunction. There are two alternative tests for determining whether  
17 a movant is entitled to injunctive relief. Under the first test, a movant must demonstrate (1)  
18 that he is likely to succeed on the merits, (2) that he is likely to suffer irreparable harm in the  
19 absence of preliminary relief, (3) that the balance of equities tips in his favor, and (4) that an  
20 injunction is in the public interest. *Winter v. Natural Res. Def. Council, Inc.*, 129 S. Ct. 365,  
21 374 (2008). Under the second test, a movant must show "serious questions going to the  
22 merits and a hardship balance that tips sharply towards [the movant] . . . so long as [the  
23 movant] also shows a likelihood of irreparable injury and that the injunction is in the public  
24 interest." *Alliance for Wild Rockies v. Cottrell*, No. 09-35756, 2010 WL 3665149, \*8 (9th  
25 Cir. Sept. 22, 2010). This latter test grants District Courts discretion "to preserve the *status*

26 \_\_\_\_\_  
27 presumably, there are procedures individuals must follow for the importation of such  
28 substances into the United States. It is unclear what those procedures are and whether  
Defendants complied with them.

1 *quo* with provisional relief until the merits [can] be sorted out.” *Id.* at \*7-8 (*quoting Save*  
2 *Strawberry Canyon v. Dep’t of Energy*, 2009 WL 1098888, at \*1-3 (N.D. Cal. Apr. 22,  
3 2009)).

4 In the context of a capital case, the Supreme Court has emphasized that these  
5 principles apply when a condemned prisoner asks a federal court to enjoin his impending  
6 execution because “[f]iling an action that can proceed under § 1983 does not entitle the  
7 complainant to an order staying an execution as a matter of course.” *Hill v. McDonough*, 547  
8 U.S. 573, 583-84 (2006). Rather, “a stay of execution is an equitable remedy” and “equity  
9 must be sensitive to the State’s strong interest in enforcing its criminal judgments without  
10 undue interference from the federal courts.” *Id.* at 584. In addition, “[a] court may consider  
11 the last-minute nature of an application to stay execution in deciding whether to grant  
12 equitable relief.” *Beardslee v. Woodford*, 395 F.3d 1064, 1068 (9th Cir. 2005) (*quoting*  
13 *Gomez v. United States District Court*, 503 U.S. 653, 654 (1991)). Thus, courts “must  
14 consider not only the likelihood of success on the merits and the relative harms to the parties,  
15 but also the extent to which the inmate has delayed unnecessarily in bringing the claim.” *Id.*  
16 (*quoting Nelson v. Campbell*, 541 U.S. 637, 649-50 (2004)).

## 17 **II. Factual Allegations**

18 In his motion for injunctive relief, Plaintiff asserts that Hospira, Inc., is the only FDA-  
19 approved manufacturer of sodium thiopental, and that Hospira ceased manufacturing the drug  
20 around the time the State sought a warrant to execute Plaintiff. (Doc. 3 at 5.) Because the  
21 State admitted during oral argument before the Arizona Supreme Court that ADOC’s supply  
22 of sodium thiopental was not manufactured by Hospira, Plaintiff contends that it must have  
23 been imported from a foreign country and that drugs from foreign countries “do not have the  
24 same assurance of safety as drugs actually regulated by the FDA.” (*Id.* at 9-10 (*citing In re*  
25 *Canadian Import Antitrust Litigation*, 470 F.3d 785, 789 (8th Cir. 2006).) According to  
26 Plaintiff, because ADOC’s supply of sodium thiopental lacks the appropriate safeguards, it  
27 could be “contaminated with toxins that cause pain, as opposed to unconsciousness” or could  
28 fail to properly anesthetize him, thus resulting in excruciating pain when the second and third

1 drugs are administered. (*Id.* at 4, 10.) Plaintiff further alleges that Arizona has feasible  
2 alternatives – it can obtain sodium thiopental from Hospira when the company starts  
3 manufacturing the drug again in early 2011, or it can use another available, FDA-approved  
4 barbiturate. (*Id.* at 10.)

5 In support of his motion, Plaintiff has proffered a declaration from Dr. John D.  
6 Palmer, a medical doctor with expertise in clinical pharmacology, who asserts that “FDA  
7 approval ensures that the product [is] pure and free of potentially harmful contaminants  
8 produced in the production of the product” and that it “actually contains the amount and  
9 concentration of drug as indicated on the label.” (Doc. 3, Ex. F at 3.) Dr. Palmer cites as an  
10 example of the importance of FDA involvement in foreign prescription drug production an  
11 outbreak of life-threatening adverse reactions from contaminated heparin, a blood thinner,  
12 produced in Chinese facilities. (*Id.*) Plaintiff further cites testimony from the FDA’s  
13 Associate Commissioner for Regulatory Affairs, who testified at a congressional hearing in  
14 2004 that “[m]any drugs obtained from foreign sources that either purport to be or appear to  
15 be the same as U.S.-approved prescription drugs are, in fact, of unknown quality. . . . These  
16 outlets may dispense expired, subpotent, contaminated or counterfeit product, the wrong or  
17 a contraindicated product.” (*Id.* at 8 (citing Statement of John M. Taylor, III, to the Senate  
18 Permanent Subcommittee on Investigations, Committee on Governmental Affairs, July 22,  
19 2004).) In his reply brief, Plaintiff provides a letter from the FDA to the Governor of Texas  
20 reiterating that drugs from foreign sources are of unknown quality and stating that the FDA  
21 “cannot provide adequate assurance . . . that drugs from foreign countries are the same as  
22 products approved by the FDA.” (Doc. 10, Ex. I.)

23 In response to Plaintiff’s motion for injunctive relief, Defendants contend that  
24 Arizona’s protocol provides sufficient safeguards to ensure that a prisoner is unconscious  
25 before ADOC administers the second and third drugs. (Doc. 7 at 4-6.) Specifically, the  
26 protocol requires the medical team to use equipment to monitor the prisoner’s condition and  
27 to conduct a thorough physical examination to determine whether the prisoner is  
28 unconscious. Therefore, according to Defendants, there is no genuine risk Plaintiff will

1 suffer excruciating pain during the execution, regardless of the quality or source of the  
2 sodium thiopental. Defendants also assert that neither the Arizona protocol nor controlling  
3 law requires a state to acquire lethal injection drugs only from FDA-approved manufacturers.  
4 (*Id.* at 6.) Defendants make *no effort* to rebut Plaintiff’s claim that there is a risk the sodium  
5 thiopental, if contaminated, could itself cause unnecessary pain and suffering.<sup>5</sup>

### 6 **III. Eighth Amendment Principles**

7 The Eighth Amendment “prohibits punishments that involve the unnecessary and  
8 wanton inflictions of pain, or that are inconsistent with evolving standards of decency that  
9 mark the progress of a maturing society.” *Cooper v. Rimmer*, 379 F.3d 1029, 1032 (9th Cir.  
10 2004). That prohibition necessarily applies to the punishment of death, precluding  
11 executions that “involve torture or a lingering death, or do not accord with the dignity of  
12 man.” *Beardslee*, 395 F.3d at 1070. A violation of the Eighth Amendment can be  
13 established by demonstrating a “substantial risk of serious harm.” *Farmer v. Brennan*, 511  
14 U.S. 825, 842 (1994).

15 In *Baze v. Rees*, the Supreme Court held that Kentucky’s method of execution by  
16 lethal injection was consistent with the Eighth Amendment. The decision encompassed  
17 seven separate opinions involving three blocks of Justices. In *Ventura v. State*, 2 So.3d 194,  
18 200 (Fla. 2009), the Florida Supreme Court observed that the *Baze* plurality:

19 adopted a version of the substantial-risk standard, while Justice Breyer,  
20 concurring in the judgment, and Justices Ginsburg and Souter, dissenting,  
21 adopted a version of the unnecessary-risk standard. In contrast, Justices  
22 Thomas and Scalia renounced any risk-based standard in favor of a rule of law  
23 that would uphold any method of execution which does not involve the  
*purposeful* infliction of “pain and suffering beyond that necessary to cause  
death.” Justice Stevens did not provide a separate standard but, instead,  
expressed general disagreement with (1) the death penalty based upon his long

---

24 <sup>5</sup> Defendants have repeatedly misconstrued this issue. Defendants stress that  
25 Arizona’s protocol ensures that pancuronium bromide and potassium chloride will be  
26 administered only to an unconscious prisoner. While the protocol does offer safeguards in  
27 the event that inferior sodium thiopental fails to properly anesthetize Plaintiff, those  
28 safeguards do nothing to prevent the risk of harm from contaminants or a counterfeit product.  
A core portion of Plaintiff’s claim—a portion Defendants choose to ignore—is that there may  
be a substantial risk of serious harm due to the administration of the sodium thiopental itself.

1 experience with these cases and the purported erosion of the penalty's  
2 theoretical underpinnings (deterrence, incapacitation, and retribution), and (2)  
the allegedly unnecessary use of the paralytic drug pancuronium bromide.

3 *Id.* at 199-200 (citations and footnotes omitted). In response to Justice Stevens's suggestion  
4 that the plurality opinion leaves the disposition of other cases uncertain, Chief Justice  
5 Roberts wrote:

6 [T]he standard we set forth here resolves more challenges than [Justice  
7 Stevens] acknowledges. A stay of execution may not be granted on grounds  
8 such as those asserted here unless the condemned prisoner establishes that the  
9 State's lethal injection protocol creates a demonstrated risk of severe pain. *He  
must show that the risk is substantial when compared to the known and  
available alternatives.* A State with a lethal injection protocol similar to the  
protocol we uphold today would not create a risk that meets this standard.

10 *Baze*, 553 U.S. at 61 (emphasis added).

11 In *Baze*, the petitioners raised numerous challenges to Kentucky's protocol, but none  
12 involved the precise issue presented here: whether use of non-FDA approved sodium  
13 thiopental and the failure to disclose the source creates a substantial risk of serious harm,  
14 especially when compared to the availability of other FDA-approved barbiturates. After  
15 consideration of the pleadings and relevant law, the Court concludes Plaintiff has made as  
16 strong a showing of likelihood of success as he is able and there are serious questions  
17 regarding the merits of Plaintiff's claims. Also, the balance of hardships tips sharply in  
18 Plaintiff's favor as does the likelihood of irreparable harm. Finally, the public's interest in  
19 executing Plaintiff in a manner consistent with Eighth Amendment protections supports the  
20 issuance of a preliminary injunction. *See Cottrell*, 2010 WL 3665149, at \*4-5.

#### 21 **IV. Analysis**

22 As an initial matter, and because the issue of delay is particularly relevant in assessing  
23 a request for a stay of execution, the Court will address that issue before applying the *Winter*  
24 standard for injunctive relief.

25 Defendants argue that Plaintiff unreasonably delayed filing his § 1983 complaint and  
26 that a stay should be denied on this ground. They assert that Plaintiff was aware of the  
27 national shortage of sodium thiopental since at least May 2010 and could have brought suit  
28 sooner. Plaintiff counters that he diligently sought information from ADOC regarding its

1 acquisition of sodium thiopental as soon as he learned from a newspaper article in late  
2 September that the State’s attorney was “not optimistic about obtaining sodium thiopental.”  
3 (Doc. 3 at 13.) Furthermore, Plaintiff did not learn definitively that ADOC intended to use  
4 a non-FDA approved drug until the day before he filed the instant complaint, when the  
5 State’s attorney informed the Arizona Supreme Court that ADOC’s supply of sodium  
6 thiopental was not manufactured by Hospira. The Court agrees with Plaintiff.

7 The instant complaint does not challenge ADOC’s lethal injection protocol, a claim  
8 Plaintiff clearly could have raised years ago. Rather, his claims are limited to the  
9 administration of sodium thiopental from a non-FDA approved source. Plaintiff had no  
10 verifiable information that ADOC intended to use sodium thiopental from a non-FDA  
11 approved manufacturer prior to oral argument before the Arizona Supreme Court on October  
12 20, 2010. Without this information, Plaintiff had no basis to attack ADOC’s plan to use  
13 drugs obtained from such a source. Plaintiff filed his complaint one day after learning the  
14 relevant information. Accordingly, the Court finds that Plaintiff did not purposely delay  
15 bringing his claims; rather he pursued them aggressively “as soon as he viewed them as  
16 ripe.” *Beardslee*, 395 F.3d at 1069 (directing district courts to conduct a fact-specific inquiry  
17 to ascertain whether claims could have been brought earlier and whether a petitioner has  
18 good cause for delay). For this reason, the equitable concerns that often arise from a  
19 condemned prisoner’s last-minute attempts to manipulate the system are absent here.

20 **A. Likelihood of Success or Serious Questions Going to the Merits**

21 It is well-established that Plaintiff bears the burden of proving entitlement to  
22 injunctive relief. *Winter*, 129 S. Ct. at 374. The unique circumstances presented in this case  
23 are that Defendants have refused to provide the information to Plaintiff that would allow him  
24 to attempt to carry his burden. Defendants did not inform Plaintiff they planned on using  
25 sodium thiopental from a non-FDA-approved source until October 20, 2010. If Defendants  
26 had provided all available information regarding the particular drug on that date, Plaintiff  
27 would have had time to develop evidence showing the drug presented a substantial risk of  
28 serious harm. Given the exceptionally short time period, that showing would have been

1 difficult. But Defendants did not provide Plaintiff even this short time. Instead, Defendants  
2 refused to disclose to Plaintiff *any* information regarding the drug. Defendants maintained  
3 their refusal to disclose even after a direct Court order requiring “immediate” disclosure.  
4 Defendants have not explained how Plaintiff could show he is likely to succeed on his claims  
5 that this particular drug presents a substantial risk when Defendants have refused to provide  
6 the information from which Plaintiff could make such an argument.

7         If a prisoner is permitted to challenge his execution via a 42 U.S.C. § 1983 suit, he  
8 must be entitled to the factual information underlying his claims that is solely in the  
9 possession and control of the defendants. Were this not the case, many § 1983 suits could  
10 be defeated by defendants simply refusing to provide discovery. The Court does not believe  
11 Defendants should be allowed to effectively foreclose such challenges by refusing to provide  
12 evidence. Thus, the Court is presented with a situation where Plaintiff has made facially  
13 plausible claims, the evidence regarding those claims is solely in Defendants’ possession, and  
14 Defendants have refused to produce the evidence necessary for the Court to make an  
15 informed preliminary evaluation of those claims.

16         The most analogous case of which the Court is aware is *Brown v. Vail*, C09-5101-JCC  
17 from the Western District of Washington. There, Mr. Brown was scheduled to be executed  
18 on September 10, 2010. Mr. Brown filed an emergency motion to stay his execution on  
19 August 16, 2010. His main challenge was that the State of Washington had not shown that  
20 the members of the execution team were sufficiently competent to carry out the execution.  
21 *Brown v. Vail*, C09-5101-JCC (W.D. Wash. Aug. 31, 2010). In response to this claim, the  
22 superintendent of the Washington State Penitentiary submitted a sworn statement that each  
23 member of the execution team was sufficiently qualified. *Id.* at 16. The court concluded this  
24 evidence was sufficient to defeat Mr. Brown’s conjecture regarding untrained personnel. *Id.*  
25 at 18. The situation here is different.

26         Plaintiff did not learn the factual basis for his current claim until October 20, 2010,  
27 six days prior to his execution. Unlike the State of Washington that immediately *proffered*  
28 *evidence within its control* to defeat Mr. Brown’s claims, Defendants here have repeatedly

1 refused to provide any of the underlying factual information necessary for resolution of  
2 Plaintiff's claims. Defendants could have immediately provided Plaintiff information  
3 regarding the drug or, even better, Defendants could have submitted an affidavit stating that  
4 the drug was obtained through reputable sources and there was no reason to question that it  
5 would function as intended. Instead of these options, Defendants chose to engage in repeated  
6 motion practice attempting to prevent the release of *any* details of the drug.

7         The Court is perplexed by Defendants' behavior in this case. Based on this Court's  
8 experience, Defendants actions are highly unusual. Normally, a defendant opposing a motion  
9 for emergency injunctive relief is eager to provide the evidence showing that the plaintiff's  
10 claims lack merit. This Court has never experienced a situation such as this where a  
11 defendant opposes a motion for emergency relief by claiming it has the evidence necessary  
12 for resolution of the matter but that evidence should not be produced. Defendants have never  
13 adequately explained their rationale for withholding *all* evidence regarding the drug, and  
14 Defendants have now created a situation where a seemingly simple claim that could have  
15 been resolved well in advance of the execution must be resolved in five days – and now only  
16 eighteen hours due to further protractions created only by Defendants – without the benefit  
17 of Plaintiff having the opportunity to present fact-based arguments.

18         Based on the record, the Court concludes that use of sodium thiopental from a non-  
19 FDA-approved source raises issues regarding its efficacy and possible side-effects. The  
20 Court is unable to determine whether the drug was produced by a foreign company that  
21 follows standard operating procedures for the drug's manufacture or that has no history of  
22 contamination in manufacturing the product. Absent such evidence, the Court must accept  
23 Plaintiff's factual showing that such drugs are more likely to contain harmful contaminants.  
24 (Affidavit of Dr. John D. Palmer, Doc. 3, Ex. F at 3.) Consequently, Plaintiff has shown as  
25 much likelihood of success as he possibly could given Defendants' obstructive behavior.  
26 Alternatively, Plaintiff has made a sufficient factual showing that there are "serious questions  
27 going to the merits." *Cottrell*, No. 09-35756, 2010 WL 3665149 (9th Cir. Sept. 22, 2010).

28         The Court reiterates that it does not assume that the Eighth Amendment categorically

1 prohibits the use of non-FDA approved drugs. In fact, it seems likely that the Eighth  
2 Amendment *does not* prohibit the use of such drugs. But the issue here is not simply FDA-  
3 approval. Instead, the issue is whether there is a sufficient level of confidence that the  
4 sodium thiopental Defendants plan on using to sedate Plaintiff does not create a substantial  
5 risk of harm. FDA-approval is relevant in that drugs manufactured under FDA-guidelines  
6 are likely to perform as expected; drugs manufactured by non-FDA approved sources might  
7 not benefit from such a presumption. Without the assurance of FDA-approval, the Court is  
8 left to speculate whether the non-FDA approved drug will perform in the exact same manner  
9 as an FDA-approved drug and whether the non-FDA approved drug will cause pain and  
10 suffering. This is not a factual issue the Court can resolve by adopting Defendants’  
11 assurances that sodium thiopental “is simply a chemical compound” and the source of that  
12 compound is irrelevant. (Doc. 7 at 6).

13 **B. Irreparable Harm & Balance of Equities**

14 Having established a likelihood of success or serious questions going to the merits,  
15 the Court next assesses the relative harms to the parties that will be incurred by the grant or  
16 denial of injunctive relief and the balance of equities. With regard to the State, there appears  
17 to be little potential for significant injury. The stay Plaintiff seeks would *not* preclude  
18 Defendants from employing an alternative means of carrying out the execution. Defendants  
19 could, if they wished, substitute an available FDA-approved barbiturate or obtain sodium  
20 thiopental from Hospira when it renews manufacture of the drug in several months. Perhaps  
21 most simply, Defendants could provide the information regarding its current store of sodium  
22 thiopental to Plaintiff. Doing so would allow Plaintiff to investigate the drug and confirm  
23 it will operate as intended.<sup>6</sup> Although Plaintiff committed his crime over twenty years ago

---

24  
25 <sup>6</sup> This is not realigning the burden of proof. As mentioned earlier, a party cannot  
26 refuse to provide discovery necessary to the opposing party’s case and then claim that the  
27 opposing party’s claims fail for lack of factual support. Burdens of proof are premised on  
28 the party bearing the burden having access to relevant evidence. *See Anderson v. Liberty  
Lobby, Inc.*, 477 U.S. 242, 257 (1986) (observing plaintiff must present evidence “even  
where the evidence is likely to be within the possession of the defendant, *as long as the*

1 and the State has “a significant interest in enforcing its criminal judgments,” *Nelson*, 541  
2 U.S. at 650, it is unclear how a short, temporary stay to resolve Plaintiff’s claims will  
3 threaten that interest.

4 The potential harm to Plaintiff, on the other hand, is patent. In the absence of  
5 injunctive relief, Plaintiff will be executed in eighteen hours using a drug of unknown quality  
6 that was obtained from an unidentified, non-FDA approved source. Because Defendants  
7 have refused to provide information to Plaintiff about the source of the drug or the  
8 manufacturer, this Court cannot say that Plaintiff faces no significant risk of suffering serious  
9 harm.

10 The balance of equities favors Plaintiff because a stay could have been avoided had  
11 the State timely disclosed the source of its sodium thiopental. As previously explained, and  
12 as set forth in yet more detail below, the Court rejects Defendants’ argument that they are  
13 precluded by A.R.S. § 13-747(C) from providing information such as the source of the  
14 chemicals, labels, and lot numbers. *See* Section V.

15 Weighing the relative burdens on the parties, the Court concludes that a temporary  
16 stay of execution will allow for responsible adjudication of Plaintiff’s claims without  
17 significant damage to the State’s interest in enforcing its criminal judgments or irreparable  
18 harm to Plaintiff. *See Morales v. Cate*, Nos. 5-6-cv-219-JF-HRL, 5-6-cv-926-JF-HRL, 2010  
19 WL 3835655, at \*4 (N.D. Cal. Sept. 28, 2010) (granting stay of execution because the court  
20 did not have time prior to the execution “to render a reasoned decision and permit adequate  
21 appellate review”).

22 **C. Public Interest**

23 Finally, the Court finds that the public’s interest will not be disserved by a temporary  
24 injunction. The Court is cognizant that Plaintiff murdered Mr. Dyer over twenty years ago.  
25 However, the Court finds that no significant harm to the public interest will arise from the  
26 proper, informed, and deliberate adjudication of Plaintiff’s claims. *See, e.g., Nken v. Holder*,  
27 \_\_\_\_\_  
28 *plaintiff has had a full opportunity to conduct discovery*) (emphasis added).

1 129 S. Ct. 1749, 1757 (2009) (“A reviewing court must bring considered judgment to bear  
2 on the matter before it, but that cannot always be done quickly enough to afford relief to the  
3 party aggrieved by the order under review. The choice for a reviewing court should not be  
4 between justice on the fly or participation in what may be an ‘idle ceremony’.”). Rather,  
5 temporary injunctive relief will serve the public’s interest in executing Plaintiff in a manner  
6 consistent with the Eighth Amendment. *See Trop v. Dulles*, 356 U.S. 86, 100 (1958) (“The  
7 basic concept underlying the Eighth Amendment is nothing less than the dignity of man.  
8 While the State has the power to punish, the Amendment stands to assure that this power be  
9 exercised within the limits of civilized standards.”).

#### 10 **V. Disclosure Obligations**

11 Despite the Court previously explaining that Defendants’ statutory argument is  
12 unavailing, Defendants continue to assert that Arizona law prohibits the release of *any*  
13 information regarding the drug it plans on using. Defendants are incorrect and they must  
14 release all relevant information regarding the drug.

15 In federal question cases, such as this, state law privileges do not automatically apply.  
16 *Kerr v. U.S. Dist. Court of N. Dist. of Cal.*, 511 F.2d 192, 197 (9th Cir. 1975) (“Reference  
17 to federal law in this case is necessary on the issue of the existence and scope of the claimed  
18 privilege.”). Defendants have made no effort to establish that *federal law* somehow prevents  
19 the disclosure of this information. But even if the state law applied here, Defendants’  
20 interpretation is incorrect.

21 Arizona law provides

22 The identity of executioners and other persons who participate or  
23 perform ancillary functions in an execution and any information  
24 contained in records that would identify those persons is confidential  
and is not subject to disclosure pursuant to title 39, chapter 1, article 2.

25 A.R.S. § 13-757(C). The statute also provides that

26 If a person who participates or performs ancillary functions in an  
27 execution is licensed by a board, the licensing board shall not suspend  
or revoke the person's license as a result of the person's participation in  
an execution.

28 A.R.S. § 13-757(D). Defendants claim this statute prevents the disclosure of additional

1 information regarding the drug because disclosure of the corporations involved in the  
2 manufacture and distribution of the drug will “lead to the identity of individuals participating  
3 in an ancillary function in an execution.” (Doc. 12 at 4). This interpretation is not  
4 compelling.

5 The Arizona statute cannot be read as protecting the disclosure of any information  
6 which might eventually, somehow, lead to the “identity of executioners and other persons.”  
7 Defendants do not point to any provision in the statute itself in support of this claim. If the  
8 Arizona Legislature wished to protect all individuals potentially involved in executions, the  
9 statute should not have provided protection only to “executioners and other persons who  
10 participate or perform ancillary functions in an execution.” The statute instead would  
11 provide protection to all information conceivably related to the execution.<sup>7</sup>

## 12 CONCLUSION

13 Plaintiff has met his burden of demonstrating that a temporary stay of execution is  
14 warranted to allow the Court to fully consider his challenge to Arizona’s use of sodium  
15 thiopental obtained from an unidentified, non-FDA approved source.

16 Accordingly,

17 **IT IS HEREBY ORDERED** that Plaintiff’s Motion for a Temporary Restraining  
18 Order or a Preliminary Injunction (Doc. 3) is **GRANTED**.

19 **IT IS FURTHER ORDERED** that Defendants are enjoined from carrying out  
20 Plaintiff’s sentence of death until further order of the Court.

21 **IT IS FURTHER ORDERED** that the Motion for Reconsideration (Doc. 12) is  
22 **DENIED**. Defendants shall immediately disclose to Plaintiff the documents provided to the  
23 Court.

24 **IT IS FURTHER ORDERED** that the Motion to Seal (Doc. 17) is **DENIED**.

25 **IT IS FURTHER ORDERED** that the Clerk of Court make immediate telephonic  
26

---

27 <sup>7</sup> Defendants’ claim that this statute prevents the disclosure of the manufacturer of the  
28 sodium thiopental is puzzling given Defendants’ willingness to disclose Hospira as its prior  
source of the sodium thiopental.

1 notice of this Order to Charles L. Ryan, Director of the Arizona Department of Corrections  
2 and Carson McWilliams, Warden of the Arizona State Penitentiary at Florence, and that a  
3 copy of this Order be served on these individuals by the United States Marshal forthwith.

4 DATED this 25<sup>th</sup> day of October, 2010.

5  
6  
7  
8   
9 Roslyn O. Silver  
10 United States District Judge  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28